We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

South African drug makers may be asked to pay a "backlog fee" to help clear a pipeline of medicines waiting years for approval, according to a proposal being considered by a new industry regulator. Delays for hundreds of medicines have kept the latest treatments off South African shelves and have hampered the fight against cancer, heart disease and other illnesses, in a country that also has more people receiving anti-retroviral (ARV) drugs than anywhere else in the world. Besides improving access to life-saving medication, analysts say the South African Health Products Regulatory Authority’s (Sahpra’s) proposal could help boost revenue streams for companies competing in the $3.8bn-a-year market. "It’s the first time SA offers this and we would support a backlog fee, provided it is performance-driven," said Stavros Nicolaou, senior executive for strategic trade at Aspen Pharmacare. Sahpra wants to cut the backlog and allow the regulatory assessment of all products in an "achievable ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now